

Message

From: Vallance, Patrick [I&S] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=34A3DB026A094839B977362D13396897-VALLANCE, P]
Sent: 11/05/2020 08:33:40
To: John Bell (Regius Professor) [regius@I&S]; Bingham, Kate [kate@I&S]; Jeremy Farrar [J.Farrar@I&S]
CC: Government Chief Scientific Adviser (GO-Science) [gcsa@I&S]
Subject: RE: DRAFT - Kate Bingham appointment letter (3) KB final 9 may

I agree, leave the phase 2 stuff alone and just let them get on for a bit

Patrick

From: John Bell (Regius Professor) <regius@I&S>
Sent: 11 May 2020 07:53
To: Bingham, Kate <kate@I&S>; Jeremy Farrar <J.Farrar@I&S>; Vallance, Patrick (GO-Science) <P.Vallance1@I&S>
Subject: Re: DRAFT - Kate Bingham appointment letter (3) KB final 9 may

Not at all clear what is going on here. It is true there is a minister for medicines (James Bethall) but on the therapeutics trials he has taken a back seat to Alok. Clearly a scrap between health and beis. I would stay out of it but if they pass the parcel on the phase 2 stuff one more time they will kill it once and for all!

From: Kate Bingham <kate@I&S>
Date: Monday, 11 May 2020 at 07:48
To: Jeremy Farrar <J.Farrar@I&S>, "p.vallance1@I&S" <p.vallance1@I&S>, John Bell <regius@I&S>
Subject: RE: DRAFT - Kate Bingham appointment letter (3) KB final 9 may

Still a debate in government about where therapeutics should sit – so no decision yet

From: NR @cabinetoffice.gov.uk>
Sent: 10 May 2020 20:35
To: Bingham, Kate <kate@I&S>
Cc: Elliott, Nick Mr (DES Comrcl-DG) <Nick.Elliott105@mod.gov.uk>
Subject: Update on taskforce

Kate,

Sorry for the radio silence today, we've been attempting to work your appointment and the taskforce through the system.

So we are on the same page, this is the latest:

Therapeutics has been a big topic of debate today. Whether or not we should actually add this to your remit has split opinions. We've decided it is a decision for the PM on whether or not to include it (and how we would include it) - the Health Secretary is responsible for the majority of the Therapeutics side so this might involve either moving all responsibility to the Business Secretary or having two lines of accountability. The latter feels unworkable from my perspective. We may just drop Therapeutics all together which might be easier for yourself and Nick.

With that, we've paused your **announcement** and removed your name from tomorrow's publication (this was to allow some more time to clear the above issue up). The same goes for yours and Nick's appointment letters, which remain in a good state.

Apologies that this hasn't been as smooth as I may have indicated at the beginning of the BH weekend. We are planning to have solved all of this by the time you see the PM on Tuesday. I'll keep you updated as we roll through tomorrow.

Kind regards,

NR

NR

Private Secretary to the Cabinet Secretary (National Security)

Cabinet Office | 70 Whitehall | London SW1A 2AS |

Irrelevant & Sensitive

Kate Bingham
Managing Partner, SV Health Managers LLP
71 Kingsway, London, WC2B 6ST

Irrelevant & Sensitive

www.SVHealthInvestors.com; www.TheDDFund.com

Authorised and Regulated by the Financial Conduct Authority

From: Jeremy Farrar <J.Farrar@> I&S

Sent: 10 May 2020 12:59

To: Bingham, Kate <kate@> I&S

Subject: Re: DRAFT - Kate Bingham appointment letter (3) KB final 9 may

Good summary

<https://www.nature.com/articles/d41573-020-00073-5>

From: "Bingham, Kate" <kate@> I&S

Date: Sunday, 10 May 2020 at 11:13

To: Jeremy Farrar <J.Farrar@> I&S

Subject: DRAFT - Kate Bingham appointment letter (3) KB final 9 may



This message and any attachment to it might contain confidential information and/or may be privileged or otherwise protected from disclosure. If it has been sent to you in error please do not forward it or copy it or act upon its contents, but immediately notify the sender and delete this message and any attachment from your system.

SV Health Managers LLP (registered in England number OC 308829, VAT 227 0451 34) is authorised and regulated by the Financial Conduct Authority ('FCA'). It's Firm Registration Number is 409119. The registered office is 71 Kingsway, London, WC2B 6ST.

Disclaimer Tag Type:

UKM

INQ000330574_0002